Abstract
For many years alkylating agents especially chlorambucil had been considered drugs of choice for first-line treatment of progressive and symptomatic CLL. Subsequently, treatment approaches have included purine nucleoside analogs, fludarabine or cladribine, and monoclonal antibodies (mAb). Moreover, safety and efficacy of bendamustine were investigated in an open-label, randomized, comparative trial. In March 2008 bendamustine was approved by the USA FDA for the treatment of CLL. Recently, several new agents have been explored and have shown promise in treating CLL.These treatments include new mAbs, agents targeting the antiapoptotic bcl-2 family of proteins, receptors involved in mediating survival signals from the microenvironment, antisense oligonucleotides and other agents. The most promising are new mAbs targeted CD20 molecule, lumiliximab, apolizumab, galiximab and anti-CD40 mAbs. Oblimersen, flavopiridol, thalidomide and lenalidomide are also being evaluated both in pre-clinical studies and in early clinical trials.
Keywords: CLL, bendamustin, ofatumumab, GA-101, lumiliximab, galiximab, epratuzumab, flavopiridol, oblimersen, bryostatin 1
Current Cancer Therapy Reviews
Title: New Therapies for Patients with Chronic Lymphocytic Leukemia
Volume: 4 Issue: 4
Author(s): Tadeusz Robak and Pawel Robak
Affiliation:
Keywords: CLL, bendamustin, ofatumumab, GA-101, lumiliximab, galiximab, epratuzumab, flavopiridol, oblimersen, bryostatin 1
Abstract: For many years alkylating agents especially chlorambucil had been considered drugs of choice for first-line treatment of progressive and symptomatic CLL. Subsequently, treatment approaches have included purine nucleoside analogs, fludarabine or cladribine, and monoclonal antibodies (mAb). Moreover, safety and efficacy of bendamustine were investigated in an open-label, randomized, comparative trial. In March 2008 bendamustine was approved by the USA FDA for the treatment of CLL. Recently, several new agents have been explored and have shown promise in treating CLL.These treatments include new mAbs, agents targeting the antiapoptotic bcl-2 family of proteins, receptors involved in mediating survival signals from the microenvironment, antisense oligonucleotides and other agents. The most promising are new mAbs targeted CD20 molecule, lumiliximab, apolizumab, galiximab and anti-CD40 mAbs. Oblimersen, flavopiridol, thalidomide and lenalidomide are also being evaluated both in pre-clinical studies and in early clinical trials.
Export Options
About this article
Cite this article as:
Robak Tadeusz and Robak Pawel, New Therapies for Patients with Chronic Lymphocytic Leukemia, Current Cancer Therapy Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339408786413380
DOI https://dx.doi.org/10.2174/157339408786413380 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dynorphin Convertases and their Functions in CNS
Current Pharmaceutical Design The Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM): A Review
Current Hypertension Reviews ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Exosome Limitations in the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Post Dural Puncture Headache and Hypertension
Current Hypertension Reviews The Role of Streptokinase as a Virulence Determinant of Streptococcus pyogenes – Potential for Therapeutic Targeting
Current Drug Targets Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Optimal Oxygen Therapy in the Critically Ill Patient with Respiratory Failure
Current Respiratory Medicine Reviews Non-Respiratory Manifestations of COVID-19 and Pathophysiological Evidences
New Emirates Medical Journal Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits
Current Pharmaceutical Biotechnology Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Effects of <I>Gentiana lutea</I> Root on Vascular Diseases
Current Vascular Pharmacology Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Nucleic Acid-based Molecular Treatment of Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Status of Herbal Medicines in the Treatment of Diabetes: A Review
Current Diabetes Reviews A Review of Cardiogenic Shock in Acute Myocardial Infarction
Current Cardiology Reviews The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews